382 related articles for article (PubMed ID: 11852183)
1. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.
Junn E; Mouradian MM
Neurosci Lett; 2002 Mar; 320(3):146-50. PubMed ID: 11852183
[TBL] [Abstract][Full Text] [Related]
2. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
Moussa CE; Wersinger C; Tomita Y; Sidhu A
Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
4. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
6. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
7. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
[TBL] [Abstract][Full Text] [Related]
8. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons.
Petrucelli L; O'Farrell C; Lockhart PJ; Baptista M; Kehoe K; Vink L; Choi P; Wolozin B; Farrer M; Hardy J; Cookson MR
Neuron; 2002 Dec; 36(6):1007-19. PubMed ID: 12495618
[TBL] [Abstract][Full Text] [Related]
9. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.
Kanda S; Bishop JF; Eglitis MA; Yang Y; Mouradian MM
Neuroscience; 2000; 97(2):279-84. PubMed ID: 10799759
[TBL] [Abstract][Full Text] [Related]
10. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.
Ostrerova-Golts N; Petrucelli L; Hardy J; Lee JM; Farer M; Wolozin B
J Neurosci; 2000 Aug; 20(16):6048-54. PubMed ID: 10934254
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
12. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
Zhou W; Hurlbert MS; Schaack J; Prasad KN; Freed CR
Brain Res; 2000 Jun; 866(1-2):33-43. PubMed ID: 10825478
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity.
Wersinger C; Prou D; Vernier P; Niznik HB; Sidhu A
Mol Cell Neurosci; 2003 Sep; 24(1):91-105. PubMed ID: 14550771
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
[TBL] [Abstract][Full Text] [Related]
17. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line.
Lotharius J; Barg S; Wiekop P; Lundberg C; Raymon HK; Brundin P
J Biol Chem; 2002 Oct; 277(41):38884-94. PubMed ID: 12145295
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture.
Zhou W; Schaack J; Zawada WM; Freed CR
Brain Res; 2002 Feb; 926(1-2):42-50. PubMed ID: 11814405
[TBL] [Abstract][Full Text] [Related]
19. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
20. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant.
Wersinger C; Vernier P; Sidhu A
Biochemistry; 2004 Feb; 43(5):1242-53. PubMed ID: 14756560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
